167 Results Sort By:
Use of an Arginase Inhibitor to Treat Kidney Disease
Application A method to treat cardiovascular disease in chronic kidney disease patients with an arginase inhibitor alone or in combination with arginine and/or BH4 (tetrahydrobiopterin). Key Benefits Potential new combination therapy for cardiovascular disease resulting from chronic kidney disease. Market Summary Chronic kidney disease (CKD)...
Published: 12/20/2022       Contributor(s): Loretta Reyes, Claudia Morris, Roy Sutliff
Improving Pediatric Asthma Management for Urban Families
Application Home-based family psychoeducational intervention for low-income children with persistent asthma. Key Benefits Medical and psychosocial needs of patients and family members can be addressed simultaneously. Significantly improved asthma management and caregiver stress in randomized controlled clinical trial. Market Summary Asthma...
Published: 12/6/2022       Contributor(s): Marianne Celano, Lisa Kobrynski, Chanda Holsey
Antisense Oligonucleotides Therapeutics Targeting Specific Tissues or Cells
­ Application Antisense oligonucleotide (ASO) therapies for the treatment of rare diseases and cancer. Key Benefits Novel approach to ASO therapeutics that potentially improve tissue/cell targeting capabilities. Increases the efficacy of ASOs while decrease off-target toxicity. Potential to treat a variety of genetic diseases such as cancer,...
Published: 12/20/2022       Contributor(s): Jiahui Zhang, Khalid Salaita, Hanjoong Jo
Quinazolin-4(3H)-one Derivatives as NOX-2 Inhibitors: Composition of Matter, Methods of Preparation and Their Use
Application Quinazolin-4(3H)-one derivatives as selective NOX-2 inhibitors to prevent oxidative damage. Key Benefits Small molecule NOX-2 specific inhibitor. Prevents excessive reactive oxygen species (ROS) generation rather than removing them. Selective NOX-2 inhibition offers significant advantages to development of an effective therapy against...
Published: 12/6/2022       Contributor(s): Thota Ganesh, Radhika Amaradhi, Jacek Zielonka
Discovery of A Dual Inhibitor of NQO1 and GSTP1 for Treating Malignant Glioblastoma
­ Application A small molecule compound to treat Malignant Glioblastoma multiforme. Key Benefits Dual inhibition of NQO1 and GSTP1 induces cell death in glioblastoma cells. Inhibition of NQO1 and GSTP1 by MNPC suppresses tumor growth and elongates the life span of the animals with GBM. Market Summary Approximately 30% of patients diagnosed...
Published: 12/20/2022       Contributor(s): Keqiang Ye
SARS-CoV-2 Neutralizing Human Monoclonal Antibodies
­ Application Monoclonal antibodies to SARS-CoV2 for use in COVID-19 diagnostics and therapeutics. Key Benefits Demonstrably neutralizing, important for therapeutic mAbs. Most bind both RBG and stalk portion of spike protein, useful in case SARS-CoV2 strains develop variation in RBD. Market Summary Coronavirus (COVID-19) is an infectious...
Published: 10/28/2022       Contributor(s): Jens Wrammert, Carl Davis, Mehul Suthar, Robert Kauffman
Use of miRNA-483 and its Target Genes in Treatment of Cardiovascular and Inflammatory Diseases
­ Application Therapeutic use of miR-483 mimic for treating aortic valve clarification. Key Benefits MiR-483 or mimics of miR-483 could be used as a therapeutic. Could also be a target for additional drug development toward a non-invasive therapy for aortic valve calcification. Market Summary Aortic stenosis (AS) is the most common type...
Published: 12/6/2022       Contributor(s): Hanjoong Jo, Joan Fernandez Esmerats, Nicolas (Nico) Villa-Roel
Use of MAST1 Inhibitor in Treatment of Platinum-Based Chemotherapy
­ Application A combination therapy product for treatment of patients having cisplatin-resistant cancer. Key Benefits Identified the use of MAST1 inhibitors (such as lestaurtinib) to target cisplatin-resistant cancer. Lestaurtinib sensitized cells to cisplatin treatment the most using a concentration that attenuates cell viability by less...
Published: 12/6/2022       Contributor(s): Sumin Kang, Jing Chen, Lingtao Jin
Tumor Specific CD8 T Cell TCR Sequences of HPV-Positive Head and Neck Tumors
­ Application HPV-specific CD8 TCR sequences for the treatment of HPV-positive head and neck cancer by adoptive cell therapy. Key Benefits HPV tumor antigen set is specific for HPV-positive head and neck cancer. Targeting of ‘non-classical’ HPV antigens E2 and E5. Potential to synergize and complement HPV E6/7-specific TCR therapies...
Published: 10/28/2022       Contributor(s): Rafi Ahmed, Christiane Eberhardt, Andreas Wieland
CBCT-Guided Adaptive Photon and Proton Radiotherapy
­ Application Generating synthetic MRI images from CBCT images with deep learning. Key Benefits Generate high contrast MRI images from cone-beam CT images. High quality, high contrast images to enable precise radiation treatment. Market Summary Radiation therapy (RT) is one of the most common treatment modalities for cancer and is used...
Published: 9/29/2022       Contributor(s): Xiaofeng Yang, Yang Lei, Tian Liu, Jun Zhou
1 2 3 4 5 6 7 8 9 10 ...